Potential of PET to predict the response to trastuzumab treatment in an ErbB2-positive human xenograft tumor model

Journal of Nuclear Medicine

Volumn 53, Issue 4, 2012, Pages 629-637

  Kramer Marek, Gabriela ^a   Gijsen, Merel ^b   Kiesewetter, Dale O ^c   Bennett, Ruth ^b   Roxanis, Ioannis ^d   Zielinski, Rafal ^a   Kong, Anthony ^b   Capala, Jacek ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b UNIVERSITY OF OXFORD   (United Kingdom)

^c NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERING   (United States)

^d OXFORD UNIVERSITY HOSPITALS NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

Affibody molecules; Breast cancer HER2 ErbB2; PET imaging; Trastuzumab

Indexed keywords

[2 (4 FLUOROBENZAMIDO)ETHYL]MALEIMIDE F 18; EPIDERMAL GROWTH FACTOR RECEPTOR 2; RADIOPHARMACEUTICAL AGENT; TRASTUZUMAB; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER SIZE; CLINICAL INDICATOR; CONTROLLED STUDY; DOWN REGULATION; DRUG EFFICACY; FEASIBILITY STUDY; HUMAN; HUMAN CELL; IMAGE ANALYSIS; IMMUNOHISTOCHEMISTRY; ISOTOPE TRACING; LOADING DRUG DOSE; MAINTENANCE DRUG DOSE; MOLECULAR IMAGING; MOUSE; NONHUMAN; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; TREATMENT RESPONSE; TUMOR VASCULARIZATION; TUMOR XENOGRAFT;

ANIMALS; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC AGENTS; BIOLOGICAL TRANSPORT; BLOOD VESSELS; BREAST NEOPLASMS; CELL LINE, TUMOR; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MICE; NEOVASCULARIZATION, PATHOLOGIC; POSITRON-EMISSION TOMOGRAPHY; PROTEIN STRUCTURE, TERTIARY; RECEPTOR, ERBB-2; TREATMENT OUTCOME; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84859377878     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: 10.2967/jnumed.111.096685     Document Type: Article

References (23)

1. Meric-Bernstam F, Hung MC. Advances in targeting human epidermal growth factor receptor-2 signaling for cancer therapy. Clin Cancer Res. 2006;12:6326-6330. (Pubitemid 44799700)
2. Baselga J, Swain SM. Novel anticancer targets: revisiting ERBB2 and discovering ERBB3. Nat Rev Cancer. 2009;9:463-475.
3. Tagliabue E, Balsari A, Campiglio M, Pupa SM. HER2 as a target for breast cancer therapy. Expert Opin Biol Ther. 2010;10:711-724.
4. Bange J, Zwick E, Ullrich A. Molecular targets for breast cancer therapy and prevention. Nat Med. 2001;7:548-552. (Pubitemid 32448320)
5. Scaltriti M, Verma C, Guzman M, et al. Lapatinib, a HER2 tyrosine kinase inhibitor, induces stabilization and accumulation of HER2 and potentiates trastuzumab-dependent cell cytotoxicity. Oncogene. 2009;28:803-814.
6. Klapper LN, Waterman H, Sela M, Yarden Y. Tumor-inhibitory antibodies to HER-2/ErbB-2 may act by recruiting c-Cbl and enhancing ubiquitination of HER-2. Cancer Res. 2000;60:3384-3388.
7. Gijsen M, King P, Perera T, et al. HER2 phosphorylation is maintained by a PKB negative feedback loop in response to anti-HER2 Herceptin in breast cancer. PLoS Biol. 2010;8:e1000563.
8. Clynes RA, Towers TL, Presta LG, Ravetch JV. Inhibitory Fc receptors modulate in vivo cytoxicity against tumor targets. Nat Med. 2000;6:443-446. (Pubitemid 30208162)
9. Barok M, Isola J, Palyi-Krekk Z, et al. Trastuzumab causes antibody-dependent cellular cytotoxicity-mediated growth inhibition of submacroscopic JIMT-1 breast cancer xenografts despite intrinsic drug resistance. Mol Cancer Ther. 2007;6:2065-2072. (Pubitemid 47052497)
10. Izumi Y, Xu L, di Tomaso E, Fukumura D, Jain RK. Tumour biology: Herceptin acts as an anti-angiogenic cocktail. Nature. 2002;416:279-280. (Pubitemid 34260234)
11. Romond EH, Perez EA, Bryant J, et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med. 2005;353:1673-1684. (Pubitemid 41464706)
12. Piccart-Gebhart MJ, Procter M, Leyland-Jones B, et al. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med. 2005;353:1659-1672. (Pubitemid 41464705)
13. Cobleigh MA, Vogel CL, Tripathy D, et al. Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease. J Clin Oncol. 1999;17:2639-2648. (Pubitemid 29415219)
14. Vogel CL, Cobleigh MA, Tripathy D, et al. Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer. J Clin Oncol. 2002;20:719-726. (Pubitemid 34111379)
15. Ghosh R, Narasanna A, Wang SE, et al. Trastuzumab has preferential activity against breast cancers driven by HER2 homodimers. Cancer Res. 2011;71:1871-1882.
16. 89Zr-trastuzumab and PET imaging of HER2-positive lesions in patients with metastatic breast cancer. Clin Pharmacol Ther. 2010;87:586-592.
17. Perik PJ, Lub-De Hooge MN, Gietema JA, et al. Indium-111-labeled trastuzumab scintigraphy in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer. J Clin Oncol. 2006;24:2276-2282. (Pubitemid 46630657)
18. Eigenbrot C, Ultsch M, Dubnovitsky A, Abrahmsen L, Hard T. Structural basis for high-affinity HER2 receptor binding by an engineered protein. Proc Natl Acad Sci USA. 2010;107:15039-15044.
19. Kramer-Marek G, Kiesewetter DO, Capala J. Changes in HER2 expression in breast cancer xenografts after therapy can be quantified using PET and F-18-labeled Affibody molecules. J Nucl Med. 2009;50:1131-1139.
20. Kiesewetter DO, Kramer-Marek G, Ma Y, Capala J. Radiolabeling of HER2-specific Affibody (R) molecule with F-18. J Fluor Chem. 2008;129:799-805.
21. McLarty K, Cornelissen B, Scollard DA, Done SJ, Chun K, Reilly RM. Associations between the uptake of 111In-DTPA-trastuzumab, HER2 density and response to trastuzumab (Herceptin) in athymic mice bearing subcutaneous human tumour xenografts. Eur J Nucl Med Mol Imaging. 2009;36:81-93.
22. Reddy S, Shaller CC, Doss M, et al. Evaluation of the anti-HER2 C6.5 diabody as a PET radiotracer to monitor HER2 status and predict response to trastuzumab treatment. Clin Cancer Res. 2011;17:1509-1520.
23. Hironaka S, Hasebe T, Kamijo T, et al. Biopsy specimen microvessel density is a useful prognostic marker in patients with T2-4M0 esophageal cancer treated with chemoradiotherapy. Clin Cancer Res. 2002;8:124-130. (Pubitemid 34101467)